



Pergamon

Tetrahedron Letters 40 (1999) 7135–7138

TETRAHEDRON
LETTERS

Asymmetric synthesis of the F-pyran fragment of the althohyrins

James C. Anderson* and Benjamin P. McDermott

Department of Chemistry, University of Sheffield, Sheffield, S3 7HF, UK

Received 7 July 1999; accepted 2 August 1999

Abstract

The asymmetric synthesis of a differentially protected F-pyran ring of the althohyrins has been achieved through an intramolecular cyclisation of a C₄₃ hydroxyl group onto a C₃₈–C₃₉ epoxide. Absolute stereochemistry was derived from an Evans boron aldol to control C₄₀ and C₄₁, the C₄₂–C₄₃ hydroxyl stereocentres from a Sharpless (–)-diethyl tartrate controlled epoxidation and the remaining stereocentres from substrate controlled diastereoselection. © 1999 Elsevier Science Ltd. All rights reserved.


Keywords: asymmetric synthesis; cyclisation; epoxide; pyran.

The structurally complex spongipyran macrolides, isolated from marine sponges, are extremely cytotoxic against a number of human cancer cell lines.¹ This activity has prompted a number of synthetic studies of these molecules² culminating in the total synthesis of althohyrin C by Evans³ and althohyrin A by Kishi,⁴ the structures of which serve as representatives of this class. We have also been involved with synthetic studies towards this class of molecules and wish to report our synthesis of the differentially protected F-pyran.⁵

Our retrosynthetic analysis of the althohyrins followed the proven late stage macrolactonisation and prior coupling of the northern and southern hemispheres by a Wittig reaction.² The synthesis of the southern hemisphere (**1**), the E,F-bis-pyran of the macrolide, can be simplified by *retro*-lactolisation and then aldol disconnection (Scheme 1).⁶ The stereocontrolled synthesis of differentially protected **2** was achieved through a cyclisation of the C₄₃ hydroxyl onto an epoxide derived from **3**, which represents an alternative to the published strategies for the synthesis of this ring system.^{3b,4b,5} Introduction of the Z-alkene was from Still's modification of the Wadsworth–Horner–Emmons reaction and introduction of the C₄₂ and C₄₃ hydroxyl stereocentres from regioselective hydrolysis following a (–)-diethyl tartrate controlled epoxidation. The remaining 1,2-*syn* relationship of C₄₀–C₄₁ was set up by an Evans boron aldol reaction.

Monoprotection of Z-2-butene-1,4-diol followed by Swern oxidation⁷ proceeded with concomitant isomerisation and gave the thermodynamically more stable E- α,β -unsaturated aldehyde **4** in 55% yield over two steps (Scheme 2).⁸ This was then added to the Z-boron enolate derived from **5**⁹ to give the


* Corresponding author. E-mail: j.anderson@sheffield.ac.uk



Scheme 1.

syn-aldol product **6** with a diastereoselection of greater than 95:5 judged by ^1H NMR, in excellent yield providing freshly prepared dibutylboron triflate¹⁰ was used (Scheme 2¹¹). Transamidation to the Weinreb amide,¹² protection of the C₄₁ hydroxyl as its TBS ether and treatment with DIBALH provided the protected aldehyde **7**. A *Z*-selective alkenylation reaction proceeded in high yield with complete diastereoselection according to Still's protocol.¹³ Reduction, TBS protection of the resultant primary alcohol and deprotection of the benzyl ether with LDBB^{3a,11,14} gave diene **8**. Differential epoxidation of the allylic alcohol **8** relying upon substrate controlled diastereoselection to give epoxide **9** was unsuccessful. Resorting to reagent control with (–)-diethyl tartrate under Sharpless conditions¹⁵ gave **9** as a single diastereoisomer in high yield after chromatography. Regioselective ring opening with benzoic acid under Lewis acidic conditions¹⁶ set up the required *anti* relationship between the C₄₂ and C₄₃ hydroxyl stereocentres in **10**.¹⁷ After considerable experimentation bis-TES protection of diol **10** was required before substrate controlled epoxidation with dimethyl dioxirane¹⁸ furnished the desired epoxide **11** (98%, ds 7:1). An optimal two step procedure for the formation of the pyran **12** required the selective deprotection of the TES groups and then acid induced cyclisation of the C₄₃ hydroxyl onto the C₃₉ terminus of the epoxide. After purification by chromatography the diastereoselection was upgraded to 10:1 in 83% yield over two steps. Deprotection of the benzoyl group gave a crystalline solid **13** amenable to single-crystal X-ray analysis which unequivocally confirmed the structure of this advanced intermediate.¹⁹ Standard protecting group manipulations involved protection of the 1,3-diol as its benzylidene acetal which will allow selective unmasking of the C₄₁ hydroxyl in the planned late stage macrolactonisation. Benzyl protection and then selective deprotection of the primary TBS ether gave **14**. Manipulation to methyl ketone **2** was achieved by standard means. Swern oxidation was followed by addition of methyl lithium and Dess Martin periodinane²⁰ oxidation gave **2**.²¹

We have synthesised the F-pyran of the althohyrтинs in differentially protected form in a high yielding



Scheme 2. (i) Bu_2BOTf , Et_3N , CH_2Cl_2 , -78 to 0°C ; H_2O_2 , 0°C , 99%; (ii) $\text{MeONMe}\cdot\text{HCl}$, AlMe_3 , THF, -15°C then; (iii) TBSCl , imidazole, DMF, rt 99%; (iv) DIBALH , CH_2Cl_2 , -78°C , 89%; (v) $(\text{CF}_3\text{CH}_2\text{O})_2\text{POCH}_2\text{CO}_2\text{Me}$, KHMDS , 18-C-6, THF, -78°C , 85%; (vi) DIBALH , CH_2Cl_2 , -78°C then; (vii) TBSCl , imidazole, DMF, rt, then; (viii) LDBB , THF, -78°C , 97%; (ix) $(-)\text{-DET}$, $\text{Ti}(\text{iPrO})_4$, $t\text{BuOOH}$, 4 Å mol. sieves, CH_2Cl_2 , -20°C , 82%; (x) PhCO_2H , $\text{Ti}(\text{iPrO})_4$, THF, rt, 80%; (xi) TESCl , Et_3N , CH_2Cl_2 , rt, 99%; (xii) DMO , CH_2Cl_2 , -20°C , 99%; (xiii) CSA , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (1:10), -20°C then; (xiv) CSA , CH_2Cl_2 , rt, 83%; (xv) DIBALH , CH_2Cl_2 , -78°C , 76%; (xvi) $\text{PhCH}(\text{OMe})_2$, CSA , CH_2Cl_2 , rt, 80%; (xvii) KH , BnBr , THF, 0°C , 98%; (xviii) $\text{HF}\cdot\text{Py}$, Py , THF, rt, 88%; (xix) $(\text{COCl})_2$, DMSO , CH_2Cl_2 , -78°C ; DIPEA , -78 to -40°C then; (xx) MeLi , Et_2O , -78°C then; (xxi) $\text{Dess Martin periodinane}$, Py , CH_2Cl_2 , rt, 80%

and stereoselective synthesis using a key intramolecular epoxide induced cyclisation. Aldol studies and final lactonisation to provide the E,F-bis-pyran 1 are presently under investigation and will be reported in due course.

Acknowledgements

We would like to thank the University of Sheffield and Zeneca Pharmaceuticals for financial support, Dr. Ed Griffin for helpful discussions, Mr. S. Thorpe and Mr. N. Lewus for providing mass spectra and Mr. A. Jones and Ms. J. Stanbra for determining microanalytical data.

References

- (a) Pettit, G. R.; Cichacz, Z. A.; Herald, C. L.; Gao, F.; Boyd, M. R.; Schmidt, J. M.; Hamel, E.; Bai, R. *J. Chem. Soc., Chem. Commun.* **1994**, 1605. (b) Bai, R.; Taylor, G. F.; Cichaz, Z. A.; Herald, C. L.; Kepler, J. A.; Pettit, G. R.; Hamel, E. *Biochemistry* **1995**, *34*, 9714.
- For a recent review see: Pietruszka, J. *Angew. Chem., Int. Ed. Engl.* **1998**, *37*, 2629.
- (a) Evans, D. A.; Coleman, P. J.; Diaz, L. C. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 2737. (b) Evans, D. A.; Trotter, B.; Côté, B.; Coleman, P. J. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 2741. (c) Evans, D. A.; Trotter, B. W.; Côté, B.; Coleman, P. J.; Dias, L. C.; Tyler, A. N. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 2744.

4. Guo, J.; Duffy, K. J.; Stevens, K. L.; Dalko, P. I.; Roth, R. M.; Hayward, M. M.; Kishi, Y. *Angew. Chem., Int. Ed. Engl.* **1998**, *37*, 187. (b) Hayward, M. M.; Roth, R. M.; Duffy, K. J.; Dalko, P. I.; Stevens, K. L.; Guo, J.; Kishi, Y. *Angew. Chem., Int. Ed. Engl.* **1998**, *37*, 190.
5. Syntheses of the F-pyran which we are aware include Refs. 3b, 4b and: (a) Paterson, I.; Keown, L. E. *Tetrahedron Lett.* **1997**, *38*, 5727. (b) Smith, A. B.; Zhuang, L. H.; Brook, C. S.; Boldi, A. M.; McBriar, M. D.; Moser, W. H.; Murase, N.; Nakayama, K.; Verhoest, P. R.; Lin, Q. Y. *Tetrahedron Lett.* **1997**, *38*, 8667. (c) Fernandez-Megia, E.; Gourlaouen, N.; Ley, S. V.; Rowlands, G. J. *Synlett* **1998**, 991. (d) Lemaire-Audoire, S.; Vogel, P. *Tetrahedron Lett.* **1998**, *39*, 1345. (e) Kary, P. D.; Roberts, S. M. *Tetrahedron: Asymmetry* **1999**, *10*, 217. (f) Kary, P. D.; Roberts, S. M.; Watson, D. J. *Tetrahedron: Asymmetry* **1999**, *10*, 213. (g) Micalizio, G. C.; Roush, W. R. *Tetrahedron Lett.* **1999**, *40*, 3351.
6. An identical disconnection at this juncture was reported during our studies, see Ref. 5c.
7. Mancuso, A. J.; Huang, S. L.; Swern, D. *J. Org. Chem.* **1978**, *43*, 2480.
8. This sort of isomerisation has been noted for the slightly acidic oxidant pyridinium chlorochromate, see: Corey, E. J.; Suggs, J. W. *Tetrahedron Lett.* **1975**, 2647. In this case we speculate an addition/elimination of dimethyl sulfide accompanied by C₄₂-C₄₃ bond rotation.
9. Gage, J. R.; Evans, D. A. *Org. Synth.* **1989**, *68*, 77.
10. (a) Mukaiyama, T.; Inoue, T. *Bull. Chem. Soc. Jpn.* **1980**, *53*, 174. (b) Evans, D. A.; Nelson, J. V.; Vogel, E.; Tuber, T. R. *J. Am. Chem. Soc.* **1981**, *103*, 3099.
11. The structure assigned to each new compound is in accord with IR, ¹H and ¹³C NMR, MS, HRMS and/or elemental analysis. Abbreviations: Bn=benzyl; Bz=benzoyl; CSA=camphorsulfonic acid; DET=diethyltartrate; DIBALH=diisobutylaluminum hydride; DIPEA=diisopropylethylamine; DMSO=dimethylsulfoxide; KHMDS=potassium hexamethyldisilazide; LDBB=di-*tert*-butylbiphenyllithium; Py=pyridine; TBS=*tert*-butyldimethylsilyl; TES=triethylsilyl; Tf=trifluoromethanesulfonyl.
12. (a) Basha, A.; Lipton, M.; Weinreb, S. M. *Tetrahedron Lett.* **1977**, 4171. (b) Levin, J. L.; Turos, E.; Weinreb, S. M. *Synth. Commun.* **1982**, *12*, 989. (c) Evans, D. A.; Bender, S. L.; Morris, J. *J. Am. Chem. Soc.* **1988**, *110*, 2506.
13. Still, W. C.; Gennari, C. *Tetrahedron Lett.* **1983**, *24*, 4405.
14. (a) Freeman, P. K.; Hutchinson, L. L. *J. Org. Chem.* **1980**, *45*, 1924. (b) Ireland, R. E.; Norbeck, D. W.; Mandell, G. S.; Mandel, N. S. *J. Am. Chem. Soc.* **1985**, *107*, 3285. (c) Ireland, R. E.; Smith, M. G. *J. Am. Chem. Soc.* **1988**, *110*, 854.
15. Hanson, R. M.; Sharpless, K. B. *J. Org. Chem.* **1986**, *51*, 1922.
16. Sharpless, K. B.; Caron, M. *J. Org. Chem.* **1985**, *50*, 1557.
17. A similar strategy was reported for the introduction of the C₄₂ and C₄₃ hydroxyl stereocentres during our study, see Ref. 5b.
18. (a) Murray, R. W.; Jeyaraman, R. *J. Org. Chem.* **1985**, *50*, 2847. (b) Waldemar, A.; Bialas, J.; Hadjirapoglou, L. *Chem. Ber.* **1991**, *124*, 2377.
19. We thank Mr. Harry Adams of this department for this structure determination.
20. Dess, A. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155.
21. Characterisation data for **2**, amorphous white solid, mp 88–90°C, [α]_D=–22.2 (c=0.9, CH₂Cl₂, rt), IR (thin film) 1716 cm⁻¹; ¹H NMR (250 MHz, CDCl₃) δ 0.00 (3H, s, SiMe), 0.07 (3H, s, SiMe), 0.76 (3H, d, *J*=6.7, CHMe), 0.91 (9H, s, SiⁱBu), 2.01–2.19 (1H, m, CHMe), 2.31 (3H, s, MeCO), 3.35 (1H, dt, *J*=10.1, 4.9, C₄₃-H), 3.45–3.59 (2H, m, C₄₄-H₂), 3.55 (1H, dd, *J*=10.4, 2.4, C₃₉-H), 3.81 (1H, t, *J*=10.2, CHOTBS), 3.90 (1H, d, *J*=2.1, CHOBn), 4.20 (1H, dd, *J*=10.4, 4.9, C₄₂-H), 4.45 (1H, d, *J*=11.9, PhCH₂O), 4.89 (1H, d, *J*=11.9, PhCH₂O), 5.53 (1H, s, PhCH), 7.37–7.56 (10H, m, Ar); ¹³C NMR (62.9 MHz, CDCl₃) δ 12.9, 18.4, 26.0, 27.6, 39.2, 68.6, 71.2, 73.7, 75.8, 82.7, 83.0, 83.1, 102.1, 126.4, 128.1, 128.4, 128.6, 128.7, 129.0, 136.6, 137.4, 211.5; MS (CI⁺) 527 (MH⁺); HRMS C₃₀H₄₃O₆Si calcd 527.2829, found 527.2806.